Memberships

MetrioPharm

MetrioPharm Memberships

News

MetrioPharm announces first patient dosed in a clinical phase II trial for MP1032 for the treatment of moderate-to-severe chronic plaque psoriasis - 2018-Mar-07

Zurich, March 07, 2018. MetrioPharm AG announces the first dosing of the first patient in its phase II clinical trial MP1032-CT04 on March 06, 2018.

» more

Investor Relations

MetrioPharm Investor Relations News QI 2018 - 2018-Mar-31

Topics: Greetings from Dr. Wolfgang Brysch, CEO of MetrioPharm AG, First Patient First Dose, MetrioPharm Blog, J.P. Morgen Healthcare Conference, Swiss Nordic Bio, Investor Talks in Monaco, Corporate Calendar

» more

Navigation

Home
About us
Technology
Products
Investors
Press
Contact
Blog

Social

  

Newsletter

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter

Switzerland (HQ)

MetrioPharm AG

Bleicherweg 45
8002 Zurich

Phone: +41 (44) 515 21 97

Germany (R&D)

MetrioPharm Deutschland GmbH

Am Borsigturm 100
13507 Berlin

Phone: +49 (0)30 – 3384 395 02

This website is intended for visitors from Switzerland and Germany.

Imprint
Privacy policy
Sitemap
This site uses cookies